Big Rock Partners Acquisition Corp (BRPA)
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of NRx Pharmaceuticals, Inc. and Encourages Long-Term NRXP / BRPA Shareholders to Contact the Firm
/PRNewswire/ -- Kaskela Law LLC announces that it is investigating NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx") on behalf of the company's long-term...
NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA)
- Newly formed publicly traded company NRx Pharmaceuticals, Inc. (NRx) to be traded under the ticker symbol "NRXP" on the Nasdaq Global Market
Big Rock Partners Acquisition Corp. Announces Effectiveness of Registration Statement; Confirms Annual Meeting Date of May 24, 2021 to Approve Proposed Merger with NeuroRx
Big Rock Partners Recommends All Stockholders Vote "FOR" ALL Proposals at Annual Meeting NEW YORK, NY / ACCESSWIRE / May 21, 2021 / Big Rock Partners Acquisition Corp. ("Big Rock" or "BRPA") (Nasdaq:BRPA), a publicly traded special purpose acquisition company, today confirmed that its Annual Meeting of Stockholders (the "Annual Meeting") to consider the previously announced merger agreement with
Big Rock Partners Acquisition Corp. Clarifies Procedure for Stockholder Conversions and Urges Stockholders To Vote "For" Extension Amendment Proposal
NEW YORK, NY / ACCESSWIRE / April 7, 2021 / Big Rock Partners Acquisition Corp. (Nasdaq:BRPA) ("Big Rock") today clarified the procedure for stockholder redemptions in connection with Big Rock's special meeting of stockholders called for the purpose of approving an amendment to Big Rock's amended and restated certificate of incorporation to extend the date by which Big Rock has to consummate its initial business combination from
What Will the Stock Market Do Today? 3 Big Stories to Watch.
So what will the stock market do today? It looks like investors will be waiting for updates on infrastructure spending and Archegos Capital.
/C O R R E C T I O N -- NeuroRx/
NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure
Results to be Presented at Investor Call on Monday, March 29th at 8:30am EDT
Neurorx, Inc. and Big Rock Partners Acquisition Corp. Announce Committed $10 Million Pipe to Support Proposed Business Combination
WILMINGTON, DE and DELRAY BEACH, FL / ACCESSWIRE / March 15, 2021 / NeuroRx, Inc. ("NeuroRx"), a clinical stage-small molecule pharmaceutical company and Big Rock Partners Acquisition Corp. ("Big Rock") (NASDAQ:BRPA), a special purpose acquisition company, are pleased to announce that institutional investors have committed to a private investment of $10 million in the form of one million shares of common stock of the combined
NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration
Feasibility work underway to determine the compatibility of NeuroRx's ZYESAMI™ (aviptadil, synthetic VIP) as a dry powder formulation using TFF's Thin-Film Freezing technology
NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint
NeuroRx to File for Emergency Use Authorization in This Patient Population if Positive Results Continue to be Demonstrated at Day-60 Endpoint in Line with FDA's New Guidance